||
文献分析结果
http://www.pubmedplus.cn/P/SearchQuickResult?wd=740e6575-5be2-4256-a199-5f51908389d6
01. | 无法确认 | 2 篇 | 1.739% |
02. | 2022 | 18 篇 | 15.652% |
03. | 2021 | 85 篇 | 73.913% |
04. | 2020 | 6 篇 | 5.217% |
05. | 2009 | 1 篇 | 0.870% |
01. | adv drug deliv rev | 4 篇 | 3.478% |
02. | cell | 4 篇 | 3.478% |
03. | acc chem res | 3 篇 | 2.609% |
04. | j virol | 3 篇 | 2.609% |
05. | mol cancer | 3 篇 | 2.609% |
06. | nat med | 3 篇 | 2.609% |
07. | viruses | 3 篇 | 2.609% |
08. | biomed pharmacother | 2 篇 | 1.739% |
09. | cells | 2 篇 | 1.739% |
10. | front immunol | 2 篇 | 1.739% |
01. | 美国 | 45 篇 | 39.130% |
02. | 中国 | 16 篇 | 13.913% |
03. | 德国 | 9 篇 | 7.826% |
04. | 意大利 | 8 篇 | 6.957% |
05. | 法国 | 7 篇 | 6.087% |
06. | 英国 | 6 篇 | 5.217% |
07. | 加拿大 | 5 篇 | 4.348% |
08. | 瑞士 | 5 篇 | 4.348% |
09. | 丹麦 | 4 篇 | 3.478% |
10. | 日本 | 4 篇 | 3.478% |
01. | 中国北京 | 5 篇 | 4.348% |
02. | 中国天津 | 2 篇 | 1.739% |
03. | 中国杭州 | 2 篇 | 1.739% |
04. | 中国长春 | 1 篇 | 0.870% |
05. | 中国上海 | 1 篇 | 0.870% |
06. | 中国南京 | 1 篇 | 0.870% |
07. | 中国台州 | 1 篇 | 0.870% |
08. | 中国成都 | 1 篇 | 0.870% |
09. | 中国昆明 | 1 篇 | 0.870% |
10. | 中国香港 | 1 篇 | 0.870% |
01. | Humans | 104 篇 | 90.435% |
02. | COVID-19 | 93 篇 | 80.870% |
03. | SARS-CoV-2 | 83 篇 | 72.174% |
04. | COVID-19 Vaccines | 79 篇 | 68.696% |
05. | Vaccines, Synthetic | 60 篇 | 52.174% |
06. | RNA, Messenger | 54 篇 | 46.957% |
07. | Pandemics | 43 篇 | 37.391% |
08. | Animals | 27 篇 | 23.478% |
09. | Vaccination | 24 篇 | 20.870% |
10. | Antibodies, Viral | 21 篇 | 18.261% |
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-7-28 04:29
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社